Parotid Gland Removal (Parotidectomy) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Parotidectomy — commonly referred to as parotid gland removal — is the surgical procedure to remove part or all of the parotid gland, the largest of the major salivary glands, situated bilaterally in the pre-auricular and infra-auricular regions of the face and neck.

What distinguishes parotidectomy from most other surgical gland removals is the intimate relationship between the parotid gland and the facial nerve (cranial nerve VII). The facial nerve controls the muscles responsible for all facial expression — smiling, frowning, blinking, and closing the mouth. Its branches divide within the parotid gland into five named divisions (temporal, zygomatic, buccal, marginal mandibular, and cervical). Identifying, tracing, and protecting all branches while operating within the gland is the defining technical challenge of the procedure.

Parotidectomy spans a spectrum — from partial resection of one lobe for a small benign tumour to radical total removal including sacrifice of the facial nerve for advanced cancer, followed by immediate nerve reconstruction. The appropriate extent is determined by tumour biology, location, and stage, guided by high-resolution MRI and histopathological assessment. This guide explores the full spectrum of parotid gland removal and what patients should know when considering this procedure.

Parotid gland removal is required across a range of benign, malignant, and inflammatory conditions:

• Pleomorphic adenoma: The most common salivary tumour (60–70% of parotid neoplasms). Benign but must be removed with a cuff of normal tissue; enucleation alone carries a 20–45% recurrence rate due to tumour capsule pseudopods. Long-standing lesions carry 1%/year risk of malignant transformation.
• Warthin tumour: Benign cystic tumour, most common in elderly male smokers. Bilateral in 10%. Surgery is curative; observation is appropriate in very elderly or frail patients given its indolent nature.
• Mucoepidermoid carcinoma: Most frequent primary salivary malignancy. Low-grade lesions curable by surgery; high-grade requires total parotidectomy, neck dissection, and post-operative radiotherapy.
• Adenoid cystic carcinoma: Characterised by perineural spread; may invade the facial nerve along its course. Wide surgical margins and radiotherapy are standard.
• Parotid metastases: Cutaneous squamous cell carcinoma and melanoma from the ipsilateral scalp and face frequently metastasise to intraparotid lymph nodes, requiring parotidectomy as part of regional lymph node management.
• Chronic or recurrent parotitis: Recurrent bacterial or autoimmune inflammation causing persistent pain and swelling unresponsive to medical therapy and sialendoscopy.

Candidacy depends on the nature of disease, lesion extent, patient general health, and availability of less invasive alternatives:

• Diagnostic workup: All parotid masses are evaluated with MRI (gold standard for soft tissue detail and nerve relationship) and ultrasound-guided fine-needle aspiration cytology (FNAC). PET-CT is added for clinically suspected malignancy. Diagnostic certainty from imaging and FNAC guides surgical planning.
• Benign solid tumours: All pleomorphic adenomas — regardless of size — are recommended for surgical excision given growth potential and malignant transformation risk. Small, clearly benign Warthin tumours may be observed in elderly, frail patients.
• Malignant tumours: All resectable parotid malignancies are operated on. Unresectable or metastatic disease is managed with chemoradiotherapy. N0 neck (no clinical lymphadenopathy) with high-grade primary may warrant elective neck dissection at the time of parotidectomy.
• Chronic disease: Patients with recurrent infections, multiple ductal stones, or salivary fistulas unresponsive to conservative management and sialendoscopy are candidates.
• Anaesthetic fitness: Standard cardiovascular risk assessment. Patients on blood thinners require careful pre-operative management given surgical proximity to major vessels.

The extent of parotidectomy is determined by pathology and tumour location within the gland:

• Superficial parotidectomy: Removes the superficial lobe (lateral to the facial nerve). Standard for benign tumours confined to the superficial lobe. Facial nerve is identified at its main trunk and traced distally to ensure all branches are preserved.
• Total conservative parotidectomy: Removes both superficial and deep lobes with complete preservation of the facial nerve. Used for deep lobe or large tumours and most parotid malignancies. Higher risk of temporary facial weakness than superficial parotidectomy.
• Radical parotidectomy: Total gland removal with planned facial nerve sacrifice when directly invaded by tumour. Immediately followed by cable nerve grafting (sural or great auricular nerve) to restore facial function over 6–18 months. Static reanimation procedures (gold weight implants, canthoplasty) provide immediate protection of the eye.
• Parotidectomy with neck dissection: For parotid malignancies with regional lymph node involvement or high-grade primary tumours with significant risk of occult nodal disease. Typically a level I–III neck dissection is performed simultaneously.
• Extracapsular dissection: Limited resection of small, mobile, clearly benign tumours with a tissue cuff. Controversial for pleomorphic adenoma; accepted by some guidelines for Warthin tumour and small lipomas.

Surgery offers outcomes no other intervention can reliably achieve for parotid tumours:

• Definitive treatment: Cure rates exceed 95% for benign tumours removed with adequate margins. Recurrence of pleomorphic adenoma in properly performed superficial parotidectomy is under 1%.
• Accurate tissue diagnosis: Pre-operative FNAC is not always conclusive; histopathology of the surgical specimen provides definitive diagnosis and guides adjuvant treatment for malignant lesions.
• Cancer control: Surgery is the only curative modality for resectable parotid malignancies. Five-year survival for low-grade tumours exceeds 90% after complete resection.
• Prevention of malignant transformation: Timely removal of pleomorphic adenoma prevents the escalating risk of carcinoma ex-pleomorphic adenoma, which carries a 5-year survival of only 25–65%.
• Symptom relief: Chronic parotitis, repeated abscess formation, and persistent swelling resolve completely after surgical removal.
• Cosmetic improvement: Visible or enlarging parotid masses causing facial asymmetry are eliminated; skilful reconstruction addresses the resultant contour defect.

Parotidectomy carries specific risks related to the facial nerve and surrounding anatomy:

• Temporary facial nerve paresis: Occurs in 15–40% of cases due to nerve retraction and manipulation. Expected to resolve within 3–6 months. Intraoperative facial nerve monitoring (IONM) with EMG reduces permanent injury risk and provides real-time feedback.
• Permanent facial nerve palsy: Below 1% for benign tumours in experienced centres. Higher for malignant tumours requiring nerve sacrifice; managed by immediate nerve grafting and reanimation surgery.
• Frey syndrome: Gustatory sweating (flushing, sweating on chewing) due to aberrant regeneration of parasympathetic fibres into cutaneous sweat glands. Affects 30–50% of patients; mild in most. Botulinum toxin injections provide effective, long-lasting symptom control.
• Earlobe numbness: Division of the greater auricular nerve (required for access) causes numbness of the lower ear and earlobe. Partial sensory recovery occurs over 12–18 months.
• Sialocele or salivary fistula: Accumulation of saliva in the surgical bed (5–10%). Managed conservatively with aspiration and pressure; Botox injection to suppress salivary secretion is effective for persistent cases.
• Post-parotidectomy contour defect: Depression in front of the ear after gland removal, particularly noticeable after total parotidectomy. Addressed with reconstructive fillers, flaps, or fat grafting at the time of primary surgery or subsequently.

The post-operative course after parotid gland removal is well-defined and predictable:

• Immediate post-op: Patient wakes with wound dressing and a closed suction drain. Ice packs reduce swelling. Oral analgesia with paracetamol and ibuprofen is usually sufficient. Diet: soft, moist foods for the first week.
• Days 1–3: Drain removed when output is low. Facial nerve function is formally assessed and documented. Minor wound ooze is normal. Head elevation reduces oedema.
• Weeks 2–4: Sutures removed; scar begins to mature. Facial exercises (smiling, raising eyebrows, puffing cheeks) are started immediately if any paresis is noted — early physiotherapy reduces synkinesis and promotes nerve recovery. Neck stiffness from dissection is expected; physiotherapy may be offered.
• 1–3 months: Histopathology results reviewed with oncology for malignant cases; adjuvant radiotherapy planning begins at 4–6 weeks post-operatively. Serial facial nerve function graded by the House-Brackmann scale.
• Long-term: Benign disease: annual follow-up for 5 years; MRI at 1 and 5 years for pleomorphic adenoma. Malignant disease: 3–6-monthly oncology review for first 2 years, then annually for up to 10 years with imaging as indicated.

Parotidectomy costs depend on surgical extent, pathology, adjuvant treatment needs, and geographic location:

• United States: USD 22,000–50,000 (superficial to radical parotidectomy with neck dissection)
• United Kingdom (private): GBP 12,000–20,000
• India: USD 3,500–9,000 at accredited centres
• Thailand: USD 6,000–12,000
• Turkey: USD 5,000–10,000
• Singapore: USD 10,000–18,000

Costs escalate with: total versus superficial parotidectomy, simultaneous neck dissection, intraoperative facial nerve monitoring, frozen section pathology, nerve grafting, post-parotidectomy reconstruction (fat/flap), and adjuvant radiotherapy. Medical tourists should confirm surgeon's salivary gland oncology subspecialty experience. Optimal medical tourism visit duration is 7–14 days, extended for malignant cases requiring multi-disciplinary post-operative review.

In selected clinical scenarios, alternatives to surgical removal are appropriate:

• Sialendoscopy: Endoscopic procedure for removing ductal stones (sialolithiasis) and strictures in the parotid duct without gland removal. Highly effective for obstructive disease; eliminates open surgery in suitable candidates.
• Active surveillance: Small Warthin tumours in elderly patients with significant comorbidities may be safely observed with serial ultrasound or MRI, as Warthin tumours carry minimal malignant potential and grow slowly if at all.
• Botulinum toxin injection into the parotid: Suppresses salivary secretion; effective for recurrent acute parotitis, sialoceles, and Frey syndrome. Requires repeat injections every 4–6 months. Not suitable for tumour management.
• Radiotherapy (adjuvant or definitive): Post-operative radiotherapy reduces local recurrence in high-grade parotid malignancies with positive or close margins, perineural spread, or lymph node involvement. Definitive radiotherapy alone is an option for unresectable tumours or medically unfit patients.
• Chemotherapy: Limited role in salivary gland malignancy; used in metastatic or unresectable disease. Androgen deprivation for androgen receptor-positive salivary duct carcinoma has shown promising results in recent trials.